<DOC>
	<DOC>NCT02013765</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy. The anticipated time on study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patients &gt;=18 years of age; metastatic urothelial cancer; disease progression during or after 1 prior platinumbased chemotherapy; measurable disease; HER2 overexpression (IHC [2+] or [3+]). concomitant chemotherapy or immunotherapy; active or uncontrolled infection; solely CNS metastases; clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea; coexisting malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>